NASDAQ : DWTX
Dogwood Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.28 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 43.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.75M | 6.10M | 8.70M | 3.72M | 4.25M | 4.85M |
| Research & Development | 22.78M | 21.87M | 3.53M | 1.73M | 8.07M | 10.80M |
| Operating Expenses | 29.53M | 27.97M | 12.23M | 5.45M | 12.32M | 15.64M |
| Operating Income | -29.53M | -27.97M | -12.23M | -5.45M | -12.32M | -15.64M |
| Interest Expense | -92.19K | |||||
| Interest & Investment Income | 276.35K | 96.94K | 150.90K | 67.47K | 5.67K | |
| Currency Exchange Gain (Loss) | -45.60K | -27.92K | -30.79K | |||
| EBT Excluding Unusual Items | -29.30M | -27.90M | -12.35M | -5.30M | -12.25M | -15.64M |
| Gain (Loss) on Sale of Assets | -2.73K | -2.73K | ||||
| Legal Settlements | -325.00K | |||||
| Other Unusual Items | -6.13M | |||||
| Pretax Income | -38.49M | -34.04M | -12.35M | -5.30M | -12.25M | -15.96M |
| Income Tax Expense | -2.45M | 221.10K | -503.00 | |||
| Net Income | -36.04M | -34.26M | -12.35M | -5.30M | -12.25M | -15.96M |
| Preferred Dividends & Other Adjustments | 1.26M | 514.11K | ||||
| Net Income to Common | -36.04M | -35.51M | -12.86M | -5.30M | -12.25M | -15.96M |
| Shares Outstanding (Basic) | 21.06M | 4.98M | 1.03M | 751.07K | 442.81K | 333.17K |
| Shares Outstanding (Diluted) | 21.06M | 4.98M | 1.03M | 751.07K | 442.81K | 333.17K |
| EPS (Basic) | -1.71 | -7.13 | -12.52 | -7.05 | -27.66 | -47.90 |
| EPS (Diluted) | -1.71 | -7.13 | -12.52 | -7.05 | -27.66 | -48.00 |
| EBITDA | -29.56M | -27.97M | -12.22M | |||
| D&A For EBITDA | -31.18K | 2.06K | 12.18K | |||
| EBIT | -29.53M | -27.97M | -12.23M | -5.45M | -12.32M | -15.64M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 9.61M | 6.52M | 14.85M | 3.32M | 7.03M | 14.01M |
| Cash & Short-Term Investments | 9.61M | 6.52M | 14.85M | 3.32M | 7.03M | 14.01M |
| Prepaid Expenses | 428.03K | 748.17K | 832.90K | 711.12K | 1.18M | 1.35M |
| Other Current Assets | 987.84K | 1.16M | 863.61K | 137.38K | 161.80K | 423.45K |
| Total Current Assets | 11.03M | 8.43M | 16.54M | 4.17M | 8.37M | 15.78M |
| Property, Plant & Equipment | 142.57K | 175.89K | 222.65K | |||
| Goodwill | 11.96M | 12.40M | 11.81M | |||
| Long-Term Deferred Charges | 57.35M | 69.14M | 65.71M | |||
| Other Long-Term Assets | 18.36K | 19.04K | 18.13K | |||
| Total Assets | 80.50M | 90.17M | 94.31M | 4.17M | 8.37M | 15.78M |
| Accounts Payable | 411.52K | 760.95K | 1.23M | 111.91K | 573.16K | 353.86K |
| Accrued Expenses | 2.35M | 2.24M | 1.89M | 246.63K | 470.10K | 921.76K |
| Current Portion of Leases | 57.65K | 56.84K | 49.70K | |||
| Total Current Liabilities | 2.83M | 3.06M | 3.18M | 358.55K | 1.04M | 1.28M |
| Long-Term Debt | 15.38M | |||||
| Long-Term Leases | 69.56K | 105.76K | 154.88K | |||
| Long-Term Deferred Tax Liabilities | 9.20M | 12.11M | 11.31M | |||
| Total Liabilities | 12.13M | 15.27M | 30.03M | 358.55K | 1.04M | 1.28M |
| Common Stock | 3.36K | 2.97K | 133.00 | 77.00 | 1.83K | 833.00 |
| Additional Paid-In Capital | 196.25M | 183.86M | 67.86M | 65.58M | 63.50M | 58.43M |
| Retained Earnings | -124.59M | -108.08M | -73.82M | -61.47M | -56.17M | -43.93M |
| Treasury Stock | -299.13K | -299.13K | -299.13K | -299.13K | ||
| Comprehensive Income & Other | -2.99M | -587.04K | -3.86M | |||
| Total Common Equity | 68.37M | 74.90M | -10.12M | 3.81M | 7.33M | 14.50M |
| Shareholders' Equity | 68.37M | 74.90M | 64.28M | 3.81M | 7.33M | 14.50M |
| Total Liabilities & Equity | 80.50M | 90.17M | 94.31M | 4.17M | 8.37M | 15.78M |
| Total Debt | 127.21K | 162.60K | 15.59M | |||
| Net Cash (Debt) | 9.48M | 6.36M | -737.71K | 3.32M | 7.03M | 14.01M |
| Net Cash Per Share | 0.45 | 1.28 | -0.72 | 4.42 | 15.88 | 42.04 |
| Filing Date Shares Outstanding | 33.99M | 33.40M | 1.91M | 770.32K | 733.22K | 333.22K |
| Total Common Shares Outstanding | 33.63M | 29.74M | 1.33M | 770.32K | 733.22K | 333.22K |
| Working Capital | 8.19M | 5.37M | 13.37M | 3.81M | 7.33M | 14.50M |
| Book Value Per Share | 2.03 | 2.52 | -7.60 | 4.94 | 9.99 | 43.52 |
| Tangible Book Value | 56.40M | 62.50M | -21.94M | 3.81M | 7.33M | 14.50M |
| Tangible Book Value Per Share | 1.68 | 2.10 | -16.47 | 4.94 | 9.99 | 43.52 |
| Machinery | 12.30K | 12.75K | 18.39K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -36.04M | -34.26M | -12.35M | -5.30M | -12.25M | -15.96M |
| Depreciation & Amortization | 67.42K | 68.18K | 12.18K | |||
| Other Amortization | 52.37K | 58.43K | ||||
| Loss (Gain) From Sale of Assets | 2.73K | 2.73K | ||||
| Asset Writedown & Restructuring Costs | 11.91M | 11.91M | ||||
| Stock-Based Compensation | 1.20M | 355.64K | 476.02K | 619.97K | 582.66K | 322.88K |
| Other Operating Activities | 6.80M | 6.38M | 3.59M | |||
| Change in Accounts Payable | -120.16K | -532.61K | 219.89K | -461.25K | 219.30K | 270.01K |
| Change in Other Net Operating Assets | 1.07M | 399.60K | -801.16K | 266.81K | -21.92K | -322.20K |
| Operating Cash Flow | -15.11M | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Cash Acquisitions | 3.76M | |||||
| Investing Cash Flow | 3.76M | |||||
| Long-Term Debt Issued | 3.00M | 15.32M | ||||
| Net Debt Issued (Repaid) | 3.00M | 15.32M | ||||
| Issuance of Common Stock | 11.48M | 4.34M | 1.38M | 1.16M | 4.49M | 197.56K |
| Repurchase of Common Stock | -106.27K | -351.00 | ||||
| Other Financing Activities | -53.80K | -53.80K | -295.17K | |||
| Financing Cash Flow | 11.32M | 7.28M | 16.70M | 1.16M | 4.49M | -97.60K |
| Foreign Exchange Rate Adjustments | -8.43K | 10.64K | -144.59K | |||
| Net Cash Flow | -3.79M | -8.32M | 11.53M | -3.71M | -6.98M | -15.79M |
| Levered Free Cash Flow | -16.36M | -17.34M | -5.23M | -2.98M | -6.92M | -9.80M |
| Unlevered Free Cash Flow | -16.36M | -17.39M | -5.23M | -2.98M | -6.92M | -9.80M |
| Change in Working Capital | 950.01K | -133.00K | -581.27K | -194.45K | 197.38K | -52.19K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 41.81M | 123.67M | 3.32M | 11.07M | 4.33M | 42.61M |
| Enterprise Value | 32.33M | 224.17M | 1.28M | 6.29M | -5.46M | 23.42M |
| Last Close Price | 1.28 | 4.16 | 2.49 | 14.38 | 5.90 | 127.88 |
| PB Ratio | 0.63 | 1.65 | 0.05 | 2.91 | 0.59 | 2.94 |
| P/TBV Ratio | 0.77 | 1.98 | 2.91 | 0.59 | 2.94 | |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.24 | |||
| Net Debt / Equity Ratio | -0.14 | -0.09 | 0.01 | -0.87 | -0.96 | -0.97 |
| Net Debt / EBITDA Ratio | 0.32 | 0.23 | -0.06 | |||
| Quick Ratio | 3.39 | 2.13 | 4.67 | 9.25 | 6.74 | 10.98 |
| Current Ratio | 3.89 | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 |
| Return on Equity (ROE) | -47.77% | -49.23% | -36.28% | -95.14% | -112.22% | -71.83% |
| Return on Assets (ROA) | -20.83% | -18.95% | -15.52% | -54.32% | -63.75% | -41.38% |
| Return on Capital Employed (ROCE) | -38.00% | -32.10% | -13.40% | -143.10% | -168.10% | -107.90% |
| Earnings Yield | -139.16% | -27.70% | -372.30% | -47.83% | -283.12% | -37.46% |
| Buyback Yield / Dilution | -1,355.57% | -384.29% | -36.84% | -69.62% | -32.91% | -69.06% |